苏州兰晟医药

Lansheng Pharma is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of innovative small molecule drugs for central nervous system (CNS) disorders. The company leverages a proprietary platform focused on G protein-coupled receptors (GPCRs) to address unmet medical needs in conditions such as Parkinson's disease, Alzheimer's disease, and depression. Its lead candidate, LS-007, is currently undergoing clinical trials for the treatment of Parkinson's disease. Lansheng Pharma aims to provide breakthrough therapies by targeting orphan GPCRs and optimizing blood-brain barrier penetration. The company's research and development efforts are supported by a team of experts with extensive experience in neuroscience and drug discovery.